BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/19/2015 5:28:00 PM | Browse: 838 | Download: 921
Publication Name World Journal of Hepatology
Manuscript ID 13916
Country/Territory Japan
Received
2014-09-09 08:39
Peer-Review Started
2014-09-10 08:26
To Make the First Decision
2014-12-26 13:06
Return for Revision
2014-12-31 09:29
Revised
2015-01-08 14:45
Second Decision
2015-01-28 11:36
Accepted by Journal Editor-in-Chief
2015-01-29 16:24
Accepted by Company Editor-in-Chief
2015-02-09 09:53
Articles in Press
2015-02-09 09:53
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-05-04 09:18
Publish the Manuscript Online
2015-05-19 17:28
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Antiviral therapies for chronic hepatitis C virus infection with cirrhosis
Manuscript Source Invited Manuscript
All Author List Shingo Nakamoto, Tatsuo Kanda, Hiroshi Shirasawa and Osamu Yokosuka
Funding Agency and Grant Number
Corresponding Author Tatsuo Kanda, MD, PhD, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. kandat-cib@umin.ac.jp
Key Words Hepatitis C virus; Hepatocellular carcinoma; Interferon-free regimen; Liver cirrhosis; Direct-acting antiviral agent
Core Tip In general, patients with cirrhosis who are infected with hepatitis C virus (HCV) are at a higher risk for the development of hepatocellular carcinoma (HCC) compared with patients without cirrhosis. Antiviral treatments for patients with cirrhosis and HCV may reduce the occurrence of HCC and/or prevent the progression to hepatic failure. In this review, we discussed the sustained virological response (SVR) rates of interferon-containing and interferon-free regimens for these patients. Recent advances in the development of direct-acting antivirals against HCV have improved the SVR rates and have reduced the occurrence of adverse events during treatment. Interferon-free regimens might improve the prognosis of patients with cirrhosis and HCV.
Publish Date 2015-05-19 17:28
Citation Nakamoto S, Kanda T, Shirasawa H, Yokosuka O. Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. World J Hepatol 2015; 7(8): 1133-1141
URL http://www.wjgnet.com/1948-5182/full/v7/i8/1133.htm
DOI http://dx.doi.org/10.4254/wjh.v7.i8.1133
Full Article (PDF) WJH-7-1133.pdf
Full Article (Word) WJH-7-1133.doc
Manuscript File 13916-Review.doc
Answering Reviewers 13916-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form 13916-Conflict-of-interest statement.pdf
Copyright License Agreement 13916-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 13916-Language certificate.pdf
Peer-review Report 13916-Peer-review(s).pdf
Scientific Misconduct Check 13916-Scientific misconduct check.pdf
Scientific Editor Work List 13916-Scientific editor work list.pdf